4 Small Cap Pharma Stocks With Superior Return on Equity

The Canadian small cap pharma stocks on our list are profitable with sector superior Return on Equity (ROE)

SmallCapPower | June 5, 2017: Investing in pharmaceutical companies can be risky when they are seeking FDA approval, so why not invest in the companies that have proven to be profitable? Today we have identified the four most profitably Canadian small cap pharma stocks with the best Return on Equity.

Win Big With Our Small Cap Picks

 

Medicure Inc. (TSXV: MPH) – $6.55
Pharmaceuticals

Medicure Inc. (Medicure) is a pharmaceutical company engaged in the research, clinical development and commercialization of human therapeutics. The Company operates in the biopharmaceutical industry segment. The Company’s primary operating focus is on the sale and marketing of its acute care cardiovascular drug, AGGRASTAT (tirofiban hydrochloride) owned by its subsidiary, Medicure International, Inc. and distributed in the United States and its territories through the Company’s United States subsidiary, Medicure Pharma, Inc. AGGRASTAT, a glycoprotein IIb/IIIa inhibitor (GPI), is used for the treatment of acute coronary syndrome (ACS). The Company is also engaged in the development of TARDOXAL for neurological disorders, such as Tardive Dyskinesia (TD).

  • Market Cap: $102,091,463
  • Total Revenue (LTM): $37,778,470
  • Debt to Equity: 212.3%
  • 5 Year Average ROE: 199%

Biosyent Inc. (TSXV: RX) – $7.90
Pharmaceuticals

BioSyent Inc. is a specialty pharmaceutical company. The Company, through its subsidiary, BioSyent Pharma Inc., acquires or in-licenses and develops pharmaceutical products for sale in Canada and certain international markets. It has four business units: the Community and Women’s Health Unit, which commercializes pharmaceutical products focused on improving family and women’s health; the Hospital Business Unit, which sells pharmaceutical products to hospitals and hospital specialists; the International Pharmaceutical Unit, and the Legacy Business. Its products include FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Aguettant System and Cysview.

  • Market Cap: $114,450,954
  • Total Revenue (LTM): $17,922,270
  • Debt to Equity: 0.0%
  • 5 Year Average ROE: 50%

Cipher Pharmaceuticals Inc. (TSX: CPH) – $5.62
Pharmaceuticals

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical dermatology company with a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA. Its products treat indications, such as severe nodular acne, recurrent herpes labialis, nail dystrophy, dermal ulcers, mild/moderate onychomycosis, acne, dry skin, keratosis, hyperpigmentation, hyperkeratotic actinic keratosis and high cholesterol.

  • Market Cap: $148,973,054
  • Total Revenue (LTM): $54,713,820
  • Debt to Equity: 201.9%
  • 5 Year Average ROE: 25%

Knight Therapeutics Inc. (TSX: GUD) – $9.92
Pharmaceuticals

Knight Therapeutics Inc is a Canada-based pharmaceutical company engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It finances other life sciences companies in Canada and internationally. Its prescription pharmaceuticals and medical devices in various stages of development include Impavido, AzaSite, ATryn, Photofrin, ILUVIEN, TULSA-PRO, PROBUPHINE, and NeurAxon Family of Products. In addition, the Company also has a portfolio of branded consumer health products, including Neuragen, Flat Tummy Tea, FOCUSFactor, FLEXISEQ, SEQuaderma, HandMD, UrgentRx, Laboratoire Dr. Renaud, Premiology and Pro-Derm.

  • Market Cap: $1,416,172,513
  • Total Revenue (LTM): $5,940,000
  • Debt to Equity: 0.0%
  • 5 Year Average ROE: 17%

Disclosure: Neither the author nor any of the principals at Small Cap Power, or their family members, own shares in any of the companies mentioned above.

The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. To read more of this Disclaimer please click on the button below: